Gene · 2348
Papers3,253
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 3,253
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Folate Receptor Alpha Targeted Immuno-Positron Emission Tomography Probe for Noninvasive Imaging in Triple-Negative Breast Cancer. | Chem Biomed Imaging | 2026 | 42064601 | PubTator, text mining | PubMed |
| Conjugating M13 bacteriophage targeting folate receptor alpha with multiple photosensitizers: a flexible phototheranostic platform against ovarian cancer. | J Mater Chem B | 2026 | 42052625 | PubTator, text mining | PubMed |
| Reduced folate receptor alpha (FOLR1) protein expression in fallopian tubes from premenopausal women: implications for the FOLR1 CDx assay for mirvetuximab-soravtansine therapy. | J Pathol Clin Res | 2026 | 42023640 | PubTator, text mining | PubMed |
| Proteomics Signatures of Chronic Kidney Disease in Hypertension. | Hypertension | 2026 | 42017261 | PubTator, text mining | PubMed |
| Endoscopic corpus callosotomy for drug-resistant epilepsy due to cerebral folate transporter deficiency: illustrative case. | J Neurosurg Case Lessons | 2026 | 42008842 | PubTator, text mining | PubMed |
| ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile. | Clin Cancer Res | 2026 | 42007996 | PubTator, text mining | PubMed |
| Safety and Antitumor Activity of Farletuzumab Ecteribulin in Patients With NSCLC: Phase I Expansion Results. | JTO Clin Res Rep | 2026 | 41993769 | PubTator, text mining | PubMed |
| Immunohistochemical Analysis of Potential Therapeutic Targets PRAME, FOLR1, and CLDN18.2 in Salivary Gland Carcinomas. | Cancer Med | 2026 | 41968569 | PubTator, text mining | PubMed |
| Folate Receptor α Contributes to Radiation Resistance in Neuroendocrine Prostate Cancer by Regulating Redox Homeostasis. | bioRxiv | 2026 | 41959434 | PubTator, text mining | PubMed |
| Characterizing therapeutic target antigen expression in anaplastic carcinoma of the ovary. | Gynecol Oncol Rep | 2026 | 41953531 | PubTator, text mining | PubMed |
Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. | Br J Cancer | 2026 | 41951722 | PubTator, text mining | PubMed |
| Response regarding "Folate receptor alpha as a successful biomarker in the treatment of low-grade serous ovarian cancer patients using pre-clinical and clinical models" by Wu et al. | Int J Gynecol Cancer | 2026 | 41946648 | PubTator, text mining | PubMed |
| Molecular and Clinicopathologic Features Associated With FOLR1 Expression in Gynecologic Malignancies. | Int J Gynecol Pathol | 2026 | 41944142 | PubTator, text mining | PubMed |
| Immunotherapy advancements in high-grade serous ovarian cancer: From promise to practice. | Crit Rev Oncol Hematol | 2026 | 41933852 | PubTator, text mining | PubMed |
| Turning precision medicine into reality with statistics and data-driven decision making across pharmaceutical development. | Commun Med (Lond) | 2026 | 41933168 | PubTator, text mining | PubMed |
| Does immunotherapy hold great promise in endometrial cancer care? | Front Immunol | 2026 | 41918736 | PubTator, text mining | PubMed |
| Elucidating the relationship between affinity and potency in the performance of therapeutic IgE. | Sci Rep | 2026 | 41912649 | PubTator, text mining | PubMed |
| Clinical application and optimization strategies for antibody-drug conjugates in solid tumors. | J Int Med Res | 2026 | 41904967 | PubTator, text mining | PubMed |
| HER3 and FOLR1 Expression as Actionable Targets in High-Grade Serous Ovarian Carcinoma: Prognostic and Therapeutic Implications. | Medicina (Kaunas) | 2026 | 41901574 | PubTator, text mining | PubMed |
| E-Cadherin Is an Accurate Target for Fluorescence-Guided Imaging of Lymph Nodes. | Curr Issues Mol Biol | 2026 | 41899420 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2348/papers?page=5